BIOMAT Database Logo BIOMAT Database Logo

Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon. 1984

H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker

UI MeSH Term Description Entries
D007650 Ketanserin A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione,R-41,468,R-41468,R 41,468,R 41468,R41,468,R41468
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010880 Piperidines A family of hexahydropyridines.
D011928 Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress. Cold Fingers, Hereditary,Raynaud Phenomenon,Raynaud's Disease,Raynauds Disease
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
October 1982, British medical journal (Clinical research ed.),
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
July 1987, Angiology,
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
February 1984, Arthritis and rheumatism,
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Ketanserin versus nifedipine in secondary Raynaud's phenomenon.
January 1987, VASA. Zeitschrift fur Gefasskrankheiten,
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
January 1985, Journal of cardiovascular pharmacology,
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Ketanserin: a selective antagonist of 5-HT2 serotoninergic receptors.
February 1983, Lancet (London, England),
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Treatment of Raynaud's phenomenon with ketanserin.
October 1984, British medical journal (Clinical research ed.),
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
January 1988, European journal of clinical pharmacology,
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
Ketanserin and capillary flow in Raynaud's phenomenon.
August 1990, International journal of microcirculation, clinical and experimental,
H M Bounameaux, and H Hellemans, and R Verhaeghe, and J Dequeker
International study of ketanserin in Raynaud's phenomenon.
September 1989, The American journal of medicine,
Copied contents to your clipboard!